Roxana Mincheva1, Linda Ekerljung1, Apostolos Bossios1, Bo Lundbäck1, Jan Lötvall2. 1. Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden. 2. Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden. Electronic address: jan.lotvall@gu.se.
Abstract
BACKGROUND: The prevalence of asthma severity is not well described at a population level. OBJECTIVE: We sought to determine the prevalence of phenotypic signs of asthma severity among asthmatic patients in a general population and to describe risk factors for asthma severity. METHODS: We performed an epidemiologic study conducted between 2008 and 2012 (West Sweden Asthma Study). A postal questionnaire was sent to a random population (n = 30,000) in west Sweden, with 18,087 responses. A total of 2,006 subjects were carefully phenotyped. Only subjects with "active asthma" (symptoms or medication in the last year, n = 744) were analyzed in this study to determine the degree of severity of the disease within an asthma cohort. Phenotypes of severity were calculated based on (1) multiple symptoms during the day despite ongoing use of asthma medications, (2) FEV1 of less than 70% of predicted value, (3) daily or almost daily use of rescue medications, (4) nighttime symptoms once a week or more, and (5) oral corticosteroid use/emergency department visits. Asthmatic patients were grouped as having nonsevere disease, 1 sign of severity, or 2 or more signs of severity. RESULTS: A total of 36.2% of asthmatic patients expressed at least 1 sign of asthma severity, and 13.2% had 2 or more signs. The group with 2 or more signs was older in age and had higher body mass index, a higher rate of tobacco smoking, and lower lung function. Bronchial hyperreactivity, airway inflammation, and sensitization were significantly different among the 3 groups. At a population level, the prevalence of asthma severity was 3.1% for 1 sign and 1.3% for at least 2 signs. CONCLUSION: More than 1 in 3 asthmatic patients show at least 1 sign of asthma severity. The phenotypes of asthma severity are highly diverse, which is important to consider when implementing personalized medicine in asthmatic patients.
BACKGROUND: The prevalence of asthma severity is not well described at a population level. OBJECTIVE: We sought to determine the prevalence of phenotypic signs of asthma severity among asthmatic patients in a general population and to describe risk factors for asthma severity. METHODS: We performed an epidemiologic study conducted between 2008 and 2012 (West Sweden Asthma Study). A postal questionnaire was sent to a random population (n = 30,000) in west Sweden, with 18,087 responses. A total of 2,006 subjects were carefully phenotyped. Only subjects with "active asthma" (symptoms or medication in the last year, n = 744) were analyzed in this study to determine the degree of severity of the disease within an asthma cohort. Phenotypes of severity were calculated based on (1) multiple symptoms during the day despite ongoing use of asthma medications, (2) FEV1 of less than 70% of predicted value, (3) daily or almost daily use of rescue medications, (4) nighttime symptoms once a week or more, and (5) oral corticosteroid use/emergency department visits. Asthmatic patients were grouped as having nonsevere disease, 1 sign of severity, or 2 or more signs of severity. RESULTS: A total of 36.2% of asthmatic patients expressed at least 1 sign of asthma severity, and 13.2% had 2 or more signs. The group with 2 or more signs was older in age and had higher body mass index, a higher rate of tobacco smoking, and lower lung function. Bronchial hyperreactivity, airway inflammation, and sensitization were significantly different among the 3 groups. At a population level, the prevalence of asthma severity was 3.1% for 1 sign and 1.3% for at least 2 signs. CONCLUSION: More than 1 in 3 asthmatic patients show at least 1 sign of asthma severity. The phenotypes of asthma severity are highly diverse, which is important to consider when implementing personalized medicine in asthmatic patients.
Authors: So Young Park; Jung Hyun Kim; Hyo Jung Kim; Bomi Seo; Oh Young Kwon; Hun Soo Chang; Hyouk Soo Kwon; Tae Bum Kim; Ho Kim; Choon Sik Park; Hee Bom Moon; You Sook Cho Journal: Allergy Asthma Immunol Res Date: 2018-07 Impact factor: 5.764
Authors: I Suárez-Lorenzo; F Rodríguez de Castro; D Cruz-Niesvaara; E Herrera-Ramos; C Rodríguez-Gallego; T Carrillo-Diaz Journal: Clin Transl Allergy Date: 2018-11-02 Impact factor: 5.871
Authors: Bright I Nwaru; Linda Ekerljung; Madeleine Rådinger; Anders Bjerg; Roxana Mincheva; Carina Malmhäll; Malin Axelsson; Göran Wennergren; Jan Lotvall; Bo Lundbäck Journal: BMJ Open Date: 2019-06-19 Impact factor: 2.692
Authors: Frank E van Boven; Nicolette W de Jong; Gert-Jan Braunstahl; Roy Gerth van Wijk; Lidia R Arends Journal: Clin Transl Allergy Date: 2020-01-06 Impact factor: 5.871
Authors: Mi Ae Kim; Heung Woo Park; Byung Keun Kim; So Young Park; Ga Young Ban; Ji Hyang Lee; Jin An; Ji Su Shim; Youngsoo Lee; Ha Kyeong Won; Hwa Young Lee; Kyoung Hee Sohn; Sung Yoon Kang; So Young Park; Hyun Lee; Min Hye Kim; Jae Woo Kwon; Sun Young Yoon; Jae Hyun Lee; Chin Kook Rhee; Ji Yong Moon; Taehoon Lee; So Ri Kim; Jong Sook Park; Sang Heon Kim; Jae Won Jeong; Sang Hoon Kim; Young Il Koh; Yeon Mok Oh; An Soo Jang; Kwang Ha Yoo; You Sook Cho Journal: Allergy Asthma Immunol Res Date: 2021-05 Impact factor: 5.764
Authors: Mohsen Sadatsafavi; Amir Khakban; Hamid Tavakoli; Solmaz Ehteshami-Afshar; Larry D Lynd; J Mark FitzGerald Journal: Respir Res Date: 2021-04-09